OR WAIT null SECS
January 18, 2023
Pfizer and Gero have partnered to discover potential therapeutic targets for fibrotic diseases using machine learning technology.
The collaboration between AbbVie and Anima Biotech will combine Anima's mRNA Lightning technology platform with AbbVie's extensive expertise in oncology and immunology.
January 11, 2023
The definitive agreement will give AstraZeneca global rights to CinCor’s portfolio of cardiorenal disease treatments.
Ipsen’s $952 million acquisition of Albireo is designed to bolster the company's rare disease portfolio.
Sartorius and RoosterBio will work together to address purification challenges and establish scalable downstream manufacturing processes for exosome-based therapies.
Messenger RNA is inherently unstable and thus requires unique solutions to protect its cohesion.
January 09, 2023
Astrea Bioseparations has acquired Delta Precision, a manufacturer of chromatography columns for biomanufacturing.
Avantor and Catalent have entered into a multi-year supply and services agreement.
January 04, 2023
Agilent’s acquisition of Avida grants them access to high-performance enrichment workflows that enable NGS approaches for studying cancer.
Merck, known as MSD outside of the United States and Canada, will pay Kelun-Biotech up to $9l3 billion for seven early-stage oncology treatments.